Please login to the form below
Moderna
This page shows the latest Moderna news and features for those working in and with pharma, biotech and healthcare.
IFPMA industry association conference: ‘no-one left behind’ on coronavirus vaccine
programme for their mRNA-based candidate, which uses a similar mRNA base that Moderna’s vaccine does, which is due to start phase 3 in July.
Latest news
-
CEPI-backed coronavirus vaccine from Novavax starts trials
It’s a similar picture with Moderna’s RNA-based vaccine mRNA-1273 which generated its first phase 1 data last week, setting up a phase 3 trial. ... Moderna has some data showing the antibodies stimulated by its vaccine neutralise SARS-CoV-2 in the lab
-
AZ secures capacity for one billion coronavirus vaccine doses
Meanwhile, an mRNA-based coronavirus vaccine candidate being developed by Moderna has produced initial promising results, after it stimulated COVID-19 antibodies in healthy volunteers in phase 1 testing.
-
US trials of Pfizer/BioNTech coronavirus vaccine start
Furthest ahead is an adenovirus type 5-based candidate developed by China’s CanSino Biological and the Beijing Institute of Biotechnology – which is in phase 2, a little ahead of ... Pfizer and BioNTech’s programme consists of two vaccines based on
-
J&J says COVID-19 vaccine could be ready in early 2021
J&J joins companies including Sanofi, GlaxoSmithKline, Pfizer and others in preparing for trials of COVID-19 vaccines, but at the moment US biotech Moderna is out in front, having dosed
-
Novartis forms coronavirus alliance with life sciences companies
information. Biogen has also committed $10m to support global response efforts to the COVID-19 outbreak, and a host of companies, including Gilead, Moderna, Pfizer and more are developing vaccines and
More from news
Approximately 7 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
COVID-19: the race to find a vaccine
Moderna was the first group to test a vaccine in humans, using its mRNA platform to enter the clinic in record time. ... Moderna thinks its vaccine could be available to healthcare professionals as early as the autumn, but the accepted timeline for
-
Developing a COVID-19 vaccine
At the front of the race is Cambridge, Massachusetts-based biotech company Moderna, which dosed the first patient in the US in March with its COVID-19 vaccine candidate. ... To win approval for public use, a larger phase 2 trial is need, which Moderna
-
Deal Watch September 2016
Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... up. Turning to the battle against the Zika virus, BARDA announced three more grants for vaccine development to Takeda (up to $312m), Moderna [up to
-
Deal Watch June 2016
Apart from the $200m upfront cash payment to Moderna, there were no other financials disclosed. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).
-
Deal Watch October 2015
Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls
More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
Horning has also recently joined the board of directors at Moderna, a clinical-stage biotechnology company based in Cambridge, Massachusetts.
-
Tony de Fougerolles joins Evox Therapeutics as CEO
Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.
-
Medicxi appoints former GSK chair Moncef Slaoui
Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.
-
MIT chief financial officer joins Moderna Therapeutics
US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair. ... Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's
-
PureTech Health appoints chief scientific officer
Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- GSK plans to produces one billion doses of vaccine adjuvant for COVID-19
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
